1 min read

Yeda and Weizmann Technology Transfer

Yeda manages intellectual property and licenses Weizmann research to external partners. In the Copaxone case, Weizmann scientists developed copolymer-1, Yeda licensed it to Teva, and Teva led product development and commercialization.

Miriam Bernstein

Miriam Bernstein is the pen name of Hasbara’s Resources desk. Articles on this desk are written and published automatically by artificial intelligence, with no person reviewing them before publication.

Yeda Research and Development is the Weizmann Institute’s technology-transfer company. It protects intellectual property and negotiates licenses that let outside companies develop selected discoveries. A license gives a company defined rights; it does not make the Institute the manufacturer or seller of a product.

From research to a commercial partner

A laboratory result is rarely a finished product. Moving a finding toward use can involve intellectual-property protection, partner identification, licensing, further development, testing, regulatory review, manufacturing, and distribution. Weizmann’s innovation and technology-transfer overview describes Yeda’s role in IP protection and licensing as part of this route from laboratory discovery to market.

Copaxone shows the roles clearly

Ruth Arnon, Michael Sela, and Dvora Teitelbaum developed copolymer-1 while investigating synthetic molecules related to myelin. The molecule unexpectedly suppressed an animal model of MS. Yeda licensed the technology to Teva, which pursued clinical and product development. Weizmann’s technology-transfer history identifies Copaxone among products developed from Institute research; the drug chronology records Teva’s 1995 FDA submission and the 1996 approval.

The distinct contributions matter: researchers made and studied the compound, Yeda managed the license, and Teva took responsibility for commercial development. Copaxone’s path depended on each stage rather than a single laboratory result.

Licensing is one route to impact

Yeda’s work also supports licenses and ventures based on other Institute technologies. Weizmann reports active agreements with companies and products built on Institute science. Each product has its own chain of research and development, so describing a commercial result accurately means naming the specific contribution and the partner’s role.

Sources

  1. 1.https://www.weizmann.ac.il/pages/science/research/innovation-tech-transfer
  2. 2.https://wis-wander.weizmann.ac.il/content/technology-transfer
  3. 3.https://wis-wander.weizmann.ac.il/life-sciences/cop-1-copaxone%C2%AE-story-drug

Accessibility

These settings are saved on this device.

Preview

Read clearly, your way

Adjust this page while you read. Explore resources

Text
Text sizeApplies across the site.
Colour and contrast
Theme
Motion
AnimationsMatch device follows your reduced motion setting.